Mucosal melanoma.
Seigler
Hilliard F
HF
Duke University Medical Center/Durham Veterans Administration Medical Center, Durham, North Carolina, USA. seigl001@mc.duke.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D009061:Mouth Mucosa / Q000473:pathology; D009092:Mucous Membrane / Q000473:pathology; D009297:Nasal Mucosa / Q000473:pathology; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000473:pathology; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery
D000970:Antineoplastic Agents; D007376:Interleukin-2; D007372:Interferons